Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

DRUG(1)
1 unique interventions1 categories

Analytics

Trial Phases

Phase 21

Trial Status

Other1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT04284774Phase 2Active Not Recruiting
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
Malignant Solid NeoplasmRecurrent Adrenal Gland PheochromocytomaRecurrent Ectomesenchymoma+38 more
PrincipalinvestigatorStart date: 2020-10-13

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Amir A Jazaeri

M.D. Anderson Cancer Center

Related
7 trials

Shared therapeutic areas:

Malignant Solid NeoplasmRecurrent OsteosarcomaRefractory Osteosarcoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

David Maloney

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
11 trials

Shared therapeutic areas:

Recurrent Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Edward A Neuwelt

OHSU Knight Cancer Institute

Related
6 trials

Shared therapeutic areas:

Recurrent Malignant Germ Cell TumorRecurrent Medulloblastoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Behnam Badie

City of Hope Medical Center

Related
6 trials

Shared therapeutic areas:

Recurrent Malignant GliomaRefractory Malignant Glioma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Luhua (Michael) Wang

M.D. Anderson Cancer Center

Related
13 trials

Shared therapeutic areas:

Recurrent Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Christos Fountzilas

Roswell Park Cancer Institute

Related
6 trials

Shared therapeutic areas:

Malignant Solid Neoplasm

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Arya Amini

City of Hope Medical Center

Related
7 trials

Shared therapeutic areas:

Malignant Solid Neoplasm

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Ryotaro Nakamura

City of Hope Medical Center

Related
10 trials

Shared therapeutic areas:

Malignant Solid Neoplasm

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Sarah Prinsloo

M.D. Anderson Cancer Center

Related
6 trials

Shared therapeutic areas:

Malignant Solid Neoplasm

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Bilal Omer, MD

Baylor College of Medicine

Related
7 trials

Shared therapeutic areas:

Refractory Neuroblastoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT04284774Phase 2PrincipalInvestigator

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Malignant Solid NeoplasmRecurrent Adrenal Gland PheochromocytomaRecurrent Ectomesenchymoma+38 more
Active Not Recruiting

All 1 trials loaded